Since there is a lack of data on SGLT2 inhibitor efficacy in ASD, and based on this scientific gap particularly, it is tempting to speculate that canagliflozin could be utilized in neurological disorders such as ASD. This evidence concerns the gene SLC5A2 and nervous system disorder.